Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Resveratrol counteracts lipopolysaccharide-induced depressive-like behaviors via enhanced hippocampal neurogenesis.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
- Publication Information:
Original Publication: Albany, N.Y. : Impact Journals
- Subject Terms:
- Abstract:
Radial glial-like cells (RGLs) in the adult dentate gyrus (DG) function as progenitor cells for adult hippocampal neurogenesis, a process involved in the stress-related pathophysiology and treatment efficiency of depression. Resveratrol (RSV) has been demonstrated to be a potent activator of neurogenesis. The present study investigated whether chronic RSV treatment has antidepressant potential in relation to hippocampal neurogenesis. Mice received two weeks of RSV (20 mg/kg) or dimethylsulfoxide (DMSO) treatment, followed by lipopolysaccharide (LPS; 1 mg/kg) or saline injections for 5 days. We found that RSV treatment abrogated the increased immobility in the forced swimming test and tail suspension test induced by LPS. Immunohistochemical staining revealed that RSV treatment reversed the increase in microglial activation and the inhibition in DG neurogenesis. RSV treatment also attenuated LPS-induced defects in the expanding of RGLs through promoting symmetric division. In addition, RSV ameliorated LPS-induced NF-κB activation in the hippocampus coincides with the up-regulation levels of Sirt1 and Hes1. Taken together, these data indicated that RSV-induced Sirt1 activation counteracts LPS-induced depression-like behaviors via a neurogenic mechanism. A new model to understand the role of RSV in treating depression may result from these findings.
Competing Interests: The authors have no competing financial interests.
- References:
Development. 2010 Sep;137(18):2981-7. (PMID: 20685734)
Behav Brain Res. 2000 Sep;114(1-2):199-212. (PMID: 10996061)
Mutat Res. 2008 Jan-Feb;658(1-2):68-94. (PMID: 17890139)
Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2485-94. (PMID: 22826347)
Glia. 2009 Aug 1;57(10):1082-90. (PMID: 19115386)
Int J Dev Neurosci. 2013 Nov;31(7):580-5. (PMID: 23850968)
Brain Behav Immun. 2002 Oct;16(5):602-9. (PMID: 12401475)
Brain Res. 1996 Mar 4;711(1-2):163-74. (PMID: 8680860)
Neurobiol Dis. 2013 Jan;49:177-89. (PMID: 22971966)
Eur J Pharmacol. 2015 Dec 5;768:49-57. (PMID: 26485503)
Science. 2003 Dec 5;302(5651):1760-5. (PMID: 14615545)
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43. (PMID: 9391166)
Cell. 2008 Feb 22;132(4):645-60. (PMID: 18295581)
J Neurosci. 2015 Jan 21;35(3):1011-23. (PMID: 25609618)
J Neurosci Res. 2008 Feb 1;86(2):403-10. (PMID: 17929310)
Neuropharmacology. 2012 Feb;62(2):1011-8. (PMID: 22041555)
Neurobiol Aging. 2013 Dec;34(12):2879-88. (PMID: 23855981)
Neuropsychopharmacology. 2015 Sep;40(10):2368-78. (PMID: 25833129)
PLoS One. 2015 Dec 22;10(12):e0145687. (PMID: 26695764)
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):854-76. (PMID: 21093520)
Dev Neurosci. 2013;35(5):406-15. (PMID: 23970040)
Nat Rev Neurosci. 2006 Nov;7(11):883-90. (PMID: 17033683)
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4218-22. (PMID: 17560107)
Rev Neurosci. 2000;11(1):53-8. (PMID: 10716655)
Horm Behav. 2006 Sep;50(3):370-82. (PMID: 16780843)
Development. 2015 Feb 1;142(3):477-85. (PMID: 25605780)
Mol Neurobiol. 2015 Aug;52(1):464-77. (PMID: 25195698)
Cell Stem Cell. 2007 Nov;1(5):515-28. (PMID: 18371391)
Hippocampus. 2013 Dec;23(12):1383-94. (PMID: 23966332)
Med Sci Monit. 2015 May 27;21:1535-47. (PMID: 26017336)
Mol Neurobiol. 2016 Jul;53(5):2815-2825. (PMID: 25850787)
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2669-74. (PMID: 20133768)
Front Neurosci. 2013 Aug 20;7:145. (PMID: 23970848)
Cold Spring Harb Perspect Biol. 2015 Sep 01;7(9):a021303. (PMID: 26330520)
Sci Rep. 2015 Jan 28;5:8075. (PMID: 25627672)
Psychopharmacology (Berl). 2016 May;233(9):1725-37. (PMID: 26385227)
Pharmacol Biochem Behav. 2013 Dec;114-115:64-9. (PMID: 24201049)
J Cell Physiol. 2015 Oct;230(10):2390-402. (PMID: 25727991)
Neurobiol Learn Mem. 2016 Apr;130:61-70. (PMID: 26851129)
J Physiol. 2016 Apr 1;594(7):1855-73. (PMID: 26844666)
Arch Gen Psychiatry. 2010 Mar;67(3):296-303. (PMID: 20194830)
Steroids. 2015 Sep;101:37-42. (PMID: 26048446)
J Neurosci Res. 2013 May;91(5):642-59. (PMID: 23404532)
Int J Biochem Cell Biol. 2014 Jan;46:76-9. (PMID: 24269781)
Behav Brain Res. 2014 Mar 15;261:31-9. (PMID: 24333375)
Biochim Biophys Acta. 2015 Jul;1852(7):1298-310. (PMID: 25817400)
J Neurosci Res. 2007 Dec;85(16):3574-85. (PMID: 17668856)
Nature. 2015 Jul 30;523(7562):588-91. (PMID: 26176920)
J Biol Chem. 2012 Dec 14;287(51):42588-600. (PMID: 23105098)
J Ment Health Policy Econ. 2006 Jun;9(2):87-98. (PMID: 17007486)
Mol Psychiatry. 2009 May;14(5):511-22. (PMID: 18195714)
Development. 2004 Nov;131(22):5539-50. (PMID: 15496443)
Mol Psychiatry. 2014 Aug;19(8):947-57. (PMID: 24934178)
J Neuroinflammation. 2015 Jul 30;12:138. (PMID: 26224094)
J Ethnopharmacol. 2012 Feb 15;139(3):780-7. (PMID: 22197914)
Pharmacol Biochem Behav. 2005 Jul;81(3):688-93. (PMID: 15982728)
Sci Rep. 2014 Jul 09;4:5632. (PMID: 25005489)
- Contributed Indexing:
Keywords: LPS; Pathology Section; depression; neurogenesis; radial glial cells; resveratrol
- Accession Number:
0 (Antioxidants)
0 (Hes1 protein, mouse)
0 (Lipopolysaccharides)
0 (NF-kappa B)
0 (Stilbenes)
0 (Transcription Factor HES-1)
EC 3.5.1.- (Sirt1 protein, mouse)
EC 3.5.1.- (Sirtuin 1)
Q369O8926L (Resveratrol)
YOW8V9698H (Dimethyl Sulfoxide)
- Publication Date:
Date Created: 20160813 Date Completed: 20180116 Latest Revision: 20240523
- Publication Date:
20240523
- Accession Number:
PMC5302895
- Accession Number:
10.18632/oncotarget.11178
- Accession Number:
27517628
No Comments.